99% Purity CAS 137071-32-0 Pimecrolimus Powder Raw Material Pimecrolimus Pharmaceutical Pimecrolimus

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Pimecrolimus
• Product Name: Pimecrolimus
• Name: Pimecrolimus Powder
• Appearance: White or off-White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Skin Diseases
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 137071-32-0
• Mf: C43h68clno11
• MW: 810.463
• Density: 1.19
• Melting Point: 135-136 C
• Boiling Point: 866.1 C at 760 Mmhg
• Transport Package: Negotiate
• Specification: 99%
• Trademark: Dsung
• Origin: Xi′an Shaanxi
• Production Capacity: 5000kgs/Month

Product Description

99% Purity CAS 137071-32-0 Pimecrolimus Powder Raw Material Pimecrolimus Pharmaceutical Pimecrolimus

 

Product Description

Product Details

Product Name	Pimecrolimus
CAS No.	137071-32-0
MF	C43H68ClNO11
MW	810.463
Appearance and shape	White or off-White crystalline Powder

Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12. Target: Others Pimecrolimus blocks T-lymphocyte activation pathway by inhibiting calcineurin function.Pimecrolimus prevents the release of cytokines and pro-inflammatory mediators from mast cells. Pimecrolimus binds to macrophilin-12, the pimecrolimusmacrophilin complex then binds to the cytosolic enzyme calcineurin phosphatase.The pimecrolimus-macrophilin complex prevents the dephosphorylation of the cytoplasmic component of the nuclear factor of activated T cells by inhibiting the action of calcineurin.Pimecrolimus inhibits not only the transcription and synthesis of cytokines from mast cells, but also the release of preformed mediators serotonin and β-hexosaminidase by the inhibition of Fcε-RI-mediated degranulation and secretion.

Application&Function

Pimecrolimus is a semi-synthetic, macrocyclic lactone derived from ascomycin by activation of the 32-hydroxy group with a triflate ester, and nucleophilic substitution with chloride under phase transfer conditions to provide the chloro analogue.  Pimecrolimus has been targeted for treatment of inflammatory skin disorders.  Like all tacrolimus analogues, pimecrolimus binds to receptor protein, FKBP12.The complex then binds to mTOR preventing it from interacting with target proteins.  Pimecrolimus is extensively cited in the literature with over 2,000 citations.

Specification